Patents by Inventor T.G. Murali Dhar
T.G. Murali Dhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11701373Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: May 4, 2021Date of Patent: July 18, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Publication number: 20230167131Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.Type: ApplicationFiled: February 11, 2021Publication date: June 1, 2023Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo
-
Publication number: 20230093404Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, pharmaceutically acceptable salts thereof, wherein all substituents are defined herein.Type: ApplicationFiled: January 22, 2021Publication date: March 23, 2023Inventors: Qingjie Liu, T.G. Murali Dhar
-
Publication number: 20220331346Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: May 4, 2021Publication date: October 20, 2022Inventors: Alaric J. DYCKMAN, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 11078186Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: November 8, 2017Date of Patent: August 3, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, Bin Jiang, T. G. Murali Dhar, Zhonghui Lu, Arun Kumar Gupta, Ananta Karmakar
-
Patent number: 11058696Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: May 21, 2020Date of Patent: July 13, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 11059784Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: August 8, 2018Date of Patent: July 13, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Ling Li, T. G. Murali Dhar, Hai-Yun Xiao
-
Publication number: 20210147361Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L1 is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: August 8, 2018Publication date: May 20, 2021Inventors: Alaric J. Dyckman, Ling Li, T.G. Murali Dhar, Hai-Yun Xiao
-
Patent number: 10968177Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: October 9, 2017Date of Patent: April 6, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Douglas G. Batt, T. G. Murali Dhar
-
Patent number: 10934286Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: October 12, 2017Date of Patent: March 2, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Qingjie Liu, T. G. Murali Dhar, Lan-ying Qin, Lyndon A. M. Cornelius, Hai-Yun Xiao, Jianqing Li, Robert J. Cherney
-
Patent number: 10865191Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is —(CR7R7)m—; L2 is —(CR7R7)n—; and X, Z, R1, R2, R3, R4, R5, and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: August 2, 2016Date of Patent: December 15, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Hai-Yun Xiao, T. G. Murali Dhar, Ning Li, Jingwu Duan, Bin Jiang, Zhonghui Lu, Khehyong Ngu, William J. Pitts, Joseph A. Tino
-
Publication number: 20200281952Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: May 21, 2020Publication date: September 10, 2020Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10711020Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: March 7, 2019Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Patent number: 10709719Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: November 13, 2018Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
-
Patent number: 10633354Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: August 31, 2017Date of Patent: April 28, 2020Assignee: Bristol-Myers Squibb CompanyInventors: David Marcoux, Hai-Yun Xiao, T. G. Murali Dhar, Alaric J. Dyckman
-
Patent number: 10633339Abstract: There is described a ROR? modulator of the formula (I), or stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. Also provided are pharmaceutical compositions comprising the same. The compound of the invention may be useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: May 16, 2019Date of Patent: April 28, 2020Assignee: Bristol-Myers Squibb CompanyInventors: T. G. Murali Dhar, Zili Xiao, Michael G. Yang
-
Publication number: 20200024257Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: November 8, 2017Publication date: January 23, 2020Inventors: Jingwu DUAN, Bin Jiang, T.G. Murali Dhar, Zhonghui LU, Arun Kumar Gupta, Ananta Karmakar
-
Publication number: 20190352261Abstract: There is described a ROR? modulator of the formula (I), or stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. Also provided are pharmaceutical compositions comprising the same. The compound of the invention may be useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: May 16, 2019Publication date: November 21, 2019Inventors: T.G. Murali Dhar, Zili Xiao, Michael G. Yang
-
Patent number: 10435369Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: November 8, 2017Date of Patent: October 8, 2019Assignee: Bristol-Myers Squibb CompanyInventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
-
Publication number: 20190300523Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: October 12, 2017Publication date: October 3, 2019Inventors: Qingjie LIU, T.G. Murali Dhar, Lan-ying Qin, Lyndon A.M. Cornelius, Hai-Yun Xiao, Jianqing Li, Robert J. Cherney